Persistent CD4+ T cell depression following combination alefacept and methotrexate therapy.
Bansal
Cheryl
C
Leonardi
Craig L
CL
Van Voorhees
Abby S
AS
D000293:Adolescent; D000368:Aged; D000077944:Alefacept; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D003879:Dermatologic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008297:Male; D008727:Methotrexate / Q000009:adverse effects*; D011565:Psoriasis / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins
D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077944:Alefacept; D008727:Methotrexate